Sympathetic nerve innervation and metabolism in ischemic myocardium in response to remote ischemic perconditioning

Attila Kiss1 · Ping Wu2,3 · Michaela Schlederer4 · Patrick M. Pilz1 · Petra Lujza Szabo1 · Jingle Li2 · Lukas Weber1 · Chryssoula Vraka2 · Verena Pichler2,5 · Markus Mitterhauser2,6 · Xiaoli Zhang7 · Karin Zins8 · Dietmar Abraham8 · Sijin Li3 · Bruno K. Podesser1 · Marcus Hacker2 · Xiang Li2

Received: 6 February 2022 / Revised: 29 July 2022 / Accepted: 1 August 2022 / Published online: 25 August 2022
© The Author(s) 2022

Abstract
Sympathetic nerve denervation after myocardial infarction (MI) predicts risk of sudden cardiac death. Therefore, therapeutic approaches limit infarct size, improving adverse remodeling and restores sympathetic innervation have a great clinical potential. Remote ischemic perconditioning (RIPerc) could markedly attenuate MI-reperfusion (MIR) injury. In this study, we aimed to assess its effects on cardiac sympathetic innervation and metabolism. Transient myocardial ischemia is induced by ligature of the left anterior descending coronary artery (LAD) in male Sprague–Dawley rats, and in vivo cardiac 2-[18F] FDG and [11C]mHED PET scans were performed at 14–15 days after ischemia. RIPerc was induced by three cycles of 5-min-long unilateral hind limb ischemia and intermittent 5 min of reperfusion during LAD occlusion period. The PET quantitative parameters were quantified in parametric polar maps. This standardized format facilitates the regional radioactive quantification in deficit regions to remote areas. The ex vivo radionuclide distribution was additionally identified using autoradiography. Myocardial neuron density (tyrosine hydroxylase positive staining) and chondroitin sulfate proteoglycans (CSPG, inhibiting neuron regeneration) expression were assessed by immunohistochemistry. There was no significant difference in the mean hypometabolism 2-[18F]FDG uptake ratio (44.6 ± 4.8% vs. 45.4 ± 4.4%) between MIR rats and MIR + RIPerc rats (P > 0.05). However, the mean [11C]mHED nervous activity of denervated myocardium was significantly elevated in MIR + RIPerc rats compared to the MIR rats (35.9 ± 7.1% vs. 28.9 ± 2.3%, P < 0.05), coupled with reduced denervated myocardium area (19.5 ± 5.3% vs. 27.8 ± 6.6%, P < 0.05), which were associated with preserved left-ventricular systolic function, a less reduction in neuron density, and a significant reduction in CSPG and CD68 expression in the myocardium. RIPerc presented a positive effect on cardiac sympathetic-nerve innervation following ischemia, but showed no significant effect on myocardial metabolism.

Keywords Myocardial ischemia/reperfusion · Remote ischemic perconditioning · Cardiac sympathetic nerve · Cardiac metabolism
Introduction

Myocardial infarction (MI) remains the most common cause of heart failure (HF) and it is still a leading cause of mortality and morbidity worldwide. Besides inducing cardiomyocytes death, transmural MI damages sympathetic-nerve (SN) fibers running through the infarct zone and results in regional sympathetic denervation [4, 12]. Furthermore, the SN is more vulnerable to ischemic insult than cardiomyocytes and SN denervation highly predictive of ventricular arrhythmias and sudden cardiac death [15, 21]. Despite the robust development of early revascularization and pharmacological therapy, cardiac arrhythmias and contractile dysfunction represent common consequences of remodeling and most serious complications among patients with MI [38]. Therefore, novel therapeutic strategies that effectively mitigate or reverse adverse post-infarcted cardiac remodeling and risk of sudden cardiac death are unmet need to develop. One of the most investigated cardioprotective strategy is called ischemic conditioning. In addition, remote ischemic conditioning (RIC) by applying transient, repetitive ischemia–reperfusion (IR) interventions at distant tissues or organs has emerged as a novel cardiac protective strategy to achieve protection against acute MI injury in the heart through a novel neuro and humoral pathway [26]. In general, neuronal pathway is the neuronal reflex as peripheral stimuli are processed in the brain and efferent sympathetic and parasympathetic fibers innervate the myocardium; the humoral hypothesis describes the capability of various mediators which are released during RIC procedure in the periphery and transferred by bloodstream, to protect the heart against IR injury [22, 33]. The activation of peripheral sensory nerves and then the sensory afferent transduction by RIC projected into autonomic centers of the central nervous system where the changeover to efferent vagal nerve is proceeded, and consequently, the activation of vagal nerve and downstream signaling pathways refers to cardioprotection [22]. In addition, a recent pioneering study by Kleinbongard et al. [32] further elucidated the potential importance of neuronal pathway in the cardioprotection of RIPerc in a clinically relevant pig model of myocardial infarction.

There are numbers of proof of concept clinical studies which demonstrated that remote ischemic postconditioning (RIPost) alone or combination with remote ischemic preconditioning (RIPerc) markedly improved adverse remodeling and infarct size among patients with ST-segment elevation myocardial infarction (STEMI) [11, 19, 46]. In contrast, large clinical studies failed to show the cardioprotective effect of remote ischemic preconditioning (RIPerc) in patients subjected to elective cardiac surgery [23, 37]. Furthermore, other clinical study also failed to demonstrate the cardioprotective benefit of RIC in STEMI patients [24].

In general, nerve injury, e.g., acute MI causes the ‘activation’ of peripheral glia, and the Schwann cells (SCs), which repair-specific functions affect the whole microenvironment, may provide tissue-specific support in injured organs [5, 10]. In addition, Neuregulin-1 (NRG1) and nerve growth factor-mediated signaling may also be crucial for the proliferation, survival, motility, and differentiation of SCs following a myocardial injury such as MI [9]. In line with previous reports, our group proved the positive value of RIPerc in the rat model of myocardial IR injury, associating with an increase of cardiac NRG1 expression [41]. Furthermore, previous studies also demonstrated that the delay of cardiac sympathetic reinnervation as well as the expansion of denervated infarcted myocardium significantly increase the risk of sudden cardiac death after MI [18, 25]. Collectively, cardiac sympathetic-nerve reinnervation may be an encouraging therapeutic benefits. However, there is limited approach to improve cardiac denervation after MI.

Regional quantification of cardiac SN function, in conjunction with an assessment of regional viability, is essential for investigating ischemia injury. Cardiac positron emission tomography (PET) utilizing 2-deoxy-2-[18F]fluoro-o-glucose (2-[18F]FDG) showed superior sensitivity for myocardial metabolism assessment. Of importance, PET with the [11C]labeled norepinephrine analog [11C]meta-Hydroxyephedrine ([11C]mHED) enables non-invasive identification of local cardiac SN injury in patients with HF and ischemic cardiomyopathy [1, 36]. Altogether, these reports indicate that the delay of cardiac SN innervation in infarcted and peri-infarcted tissue may be considered an essential component and surrogate marker of post-MI adverse left-ventricular (LV) remodeling and sudden cardiac death. Therefore, we assessed the effects of RIPerc on cardiac innervation and metabolism utilizing PET imaging plus immunochemistry verification, aiming to provide key evidence in developing novel pharmacological or non-pharmacological approaches for boosting early innervation, and further in reduction of cardiac mortality in patients with MI.

Methods

Animals

Male Sprague–Dawley rats (10–12 weeks old, 250–300 g, Department for Laboratory Animal Science and Genetics, Himberg, Austria) were used. The experimental protocol was approved by the Regional Ethics Committee for Laboratory Animal Experiments at the Medical University of Vienna and the Austrian Ministry of Science Research.
and Economy (BMWFV-66.009/xxx-WF/V/3b/2016), and
conforms with the Guide for the Care and Use of Laboratory
Animals, published by the US National Institutes of Health
(NIH Publication No. 85–23, revised 1996).

**Myocardial ischemia and reperfusion (MIR) injury in vivo**

Briefly, rats were anesthetized by intraperitoneal injection of a mixture of Xylazine (4 mg/kg; Bayer, Germany) and Ketamine (100 mg/kg; Dr E. Gräub AG, Switzerland), intubated (14-gauge tube), and ventilated (9 ml/kg body weight, 75–85 stroke/min). Rectal temperature was measured and maintained at 37.5–38.5 °C by a heated operating table. The heart was exposed via a left thoracotomy and a ligature was placed around the left anterior descending coronary artery (LAD) 2–3 mm away from the origin for 30 min, followed by 14–15 days of reperfusion as described previously in rats [41]. Myocardial ischemia was associated with the pallor of the myocardial area at risk and ST elevation on ECG signal. Sham rats served as controls were those completed thoracotomy but without LAD occlusion. Reperfusion was initiated following the 30 min of LAD occlusion by removal of the snare. RIPerc was induced by three cycles of 5 min of IR on hindlimb performed during myocardial ischemia as described previously [47]. Analgesia was initiated by intraperitoneal injection of Piritramide (0.1 ml/kg body weight) preoperatively and piritramide was applied in drinking water as a postoperative analgesic regimen (2 ampules of Piritramide with 30 ml of Glucose 5% in 250 ml water). Experimental protocol is depicted in Fig. 1.

**Small animal PET/CT imaging**

Fourteen days after the reperfusion, μPET scans were performed. A dedicated small animal μPET/μCT system (Inveon, Siemens Medical Solutions Inc., Erlangen, Germany) was employed. All animals were maintained under anesthesia throughout the imaging acquisition. 10 min insulinstimulated 2-[18F]FDG PET/CT (30–40 Mbq) acquisition were conducted 60 min after tracer injection, and the 10 min static [11C]mHED PET/CT (40–50 Mbq, 30 min after tracer injection) was performed on a subsequent day. All data were acquired in three-dimensional (3D) and sorted into a 3D
sonogram of 16 frames per cardiac cycle. The sinogram was reconstructed into a 128×128×95 voxel image by 2D-filtered back-projection image reconstruction using a ramp filter with the Nyquist limit (0.5 cycles/voxel) as the cut-off frequency. The voxel size equaled 0.43×0.43×0.80 mm. Data were normalized and corrected for randoms, dead time, and decay. An attenuation correction transmission scan was additionally performed before the µPET scan.

**Imaging analysis**

Late uptake defined the LV with bottle-brush sampling. Late myocardial uptake was averaged from 4 frames of data for each imaging 15–30 min after [11C]mHED injection and 45–60 min after 2-[18F]FDG injection. Using the volumetric sampling of the cardiac PET/CT scans, we defined myocardial radioactivity LV sectors and semi-automatically constructed radioactivity into cardiac metabolism and nerve polar maps. Each polar map was normalized to a region of interest (ROI) in the remote myocardium (inferior wall) at the ventricular level. The metabolism deficit or the denervation area in the myocardium was defined as 2-[18F]FDG or [11C]mHED uptake ≤ 60% of maximum activity. The uptake ratio in the defected area was defined as SUVR = mean of standardized uptake value (SUV\text{mean})/remote control myocardium uptake (SUV\text{remote}). All µPET images were analyzed using the MunichHeart/NM software package.

**Autoradiography**

The heart was excised immediately for radio assay after assessment of LV hemodynamics. Ex vivo accumulation of myocardial [11C]mHED was assessed using 20 μm sections of sample tissues with a digital autoradiography system (Cyclone® Plus Storage Phosphor System; PerkinElmer). Myocardial defect area was determined by a threshold of 60% of maximum myocardial activity in midventricular slices; the radioactivity values of the placed ROIs were drawn on short-axis slices and then were expressed as background-corrected photostimulated luminescence units per area. Measured values were normalized to account for differences in the amount of tracer injected. Then, the uptake activity of the defect area was calculated as percentages in relation to the remote area on the short-axis slice.

**Assessment of LV hemodynamics**

LV hemodynamic function was performed in vivo invasively as described previously [48]. In brief, rats were anesthetized by intraperitoneal injection of a mixture of Xylazine (4 mg/kg; Bayer, Germany) and Ketamin (100 mg/kg; Dr E. Gräub AG, Switzerland), intubated, and ventilated. The chest was opened and a microtip catheter (SPR-409, 2F, Millar Instruments, Houston, USA) was gently inserted into the LV chamber. Hemodynamic parameters such as LV systolic pressure (LVSP), LV end-diastolic pressure (LVEDP), and heart rate (HR) were continuously recorded on Labchart (v7.3.2, Powerlab System (8/30, both AD Instruments, Spechbach, Germany) connected to a Bridge Amplifier (Bridge Amp, ADInstruments, GmbH, Spechbach, Germany) and a Transducer Control unit (Model TC-510, Millar Instruments Inc., Houston, Texas, USA). In addition, transthoracic echocardiography was performed as described previously [41]. Briefly, rats were anesthetized (isoflurane 2–3%) and echocardiography was performed prior to sacrifice the rats using Vivid7 system (GE Healthcare, USA) equipped with an 11.5 MHz 10S sector transducer. Left-ventricular ejection fraction (LVEF) was evaluated.

**Histology and immunochemistry**

Tyrosine hydroxylase (TH) positive stain was performed to access the density of the neurons in myocardium. In addition, the reduction of cardiac neurons after MIR was shown to link a transient overexpression of chondroitin sulfate proteoglycans (CSPG, inhibiting neuron regeneration) in the animal hearts [18]. Therefore, we assessed immunochemistry staining for CSPG (within the infarcted area). Immunohistochemistry was also performed to evaluate the influx of CD68 + macrophages. Formalin-fixed paraffin-embedded LV cardiac tissue sections were hematoxylin and eosin (HE) stained. Streptavidin–biotin immunostaining for CD68 (1:100; mouse monoclonal, ED1, ab31630, Abcam, Cambridge, MA, USA), TH (1:100; rabbit monoclonal, EP1533Y, Abcam, Cambridge, MA, USA), and CSPG (1:500; mouse monoclonal, clone Cat-301, MAB5284, Merck, Darmstadt, Germany) were used as described previously [48]. Briefly, primary antibodies were detected with appropriate biotinylated secondary antibody (Vector Laboratories, Burlingame, CA) and horseradish peroxidase (HRP) conjugated streptavidin (Dako, Glostrup, Denmark), developed with 3,3′-diaminobenzidine (DAB) (Vector Laboratories), counterstained with hematoxylin, dehydrated, and mounted in DPX (Merck, Darmstadt, Germany). TH was developed with 3-Amino-9-ethylcarbazole (AEC) under visual control, counterstained with hematoxylin, and mounted with Aquatex (Merck, Darmstadt, Germany). Digitalized images were generated with a Nikon Eclipse 80i (Tokyo, Japan) microscope. Multiple images were obtained from each slide using ×40 objective and slides of each group were randomly selected for quantification of CD68 + macrophages and CSPG-positive areas. CD68 + macrophages were counted and results were expressed as cells per section. Quantification of CSPG-positive area in each field of view was performed using ImageJ software to measure the ratio between the positive area and the total image [31].

© Springer
Statistics

Parametric data of the three groups are presented as mean ± standard deviation (SD). Statistical analyses were performed with SPSS 24 and GraphPad Prism Software (version 7.03; GraphPad Software Inc., San Diego, CA, USA). Differences were evaluated by one-way ANOVA followed by Bonferroni post hoc test or Students’ paired t test when appropriate. P values of < 0.05 were considered statistically significant.

Results

PET imaging

Quantitative cardiac polar map of viability (2-[18F]FDG), and sympathetic innervation [11C]mHED PET images from 2 representative subjects (MIR vs MIR + RIPerc) are presented in Fig. 2. The metabolism-deficit 2-[18F] FDG area/remote area uptake ratio in the two groups (NO.: MIR = 9 vs. MIR + RIPerc = 9) showed no difference (MIR vs. MIR + RIPerc: SUVRmean = 44.6 ± 4.8 vs. 45.4 ± 4.4, P > 0.05) and there was no difference of hypometabolism area volume/global ventricular volume between MIR group and MIR + RIPerc groups (14.7 ± 4.7% vs. 15.3 ± 2.5%, P > 0.05). However, the relative [11C]mHED uptake ratio (%) in denervated myocardium to remote area was significantly elevated in the MIR + RIPerc group in comparison to the MIR group (SUVRmean = 35.9 ± 7.1 vs. 28.9 ± 2.3, P < 0.05), and the denervated area/global ventricular area was significantly decreased in MIR + RIPerc animals vs MIR group (19.5 ± 5.3% vs. 27.8 ± 6.6%, P < 0.05).

Autoradiography

Ex vivo [11C]mHED uptake ratios to the remote control region were 0.30 ± 0.14 (MIR) and 0.39 ± 0.17 (MIR + RIPerc), respectively (P < 0.01). Representative autoradiography is shown in Fig. 3.

Left-ventricular hemodynamic function

As displayed in Table 1, decreased LVSP, increased LVEDP, and reduced peak velocities of pressure change during isovolumic contraction (+dP/dt) and isovolumic relaxation (−dP/dt) in rats with MIR were observed in comparison to the sham group (P < 0.01, respectively). These parameters were improved by RIPerc, markedly in LVSP and +dP/dt. No differences between the groups were observed in HR. In
addition, LVEF significantly declined in MIR in comparison to Sham-OP (83 ± 4% vs 66 ± 4%; n = 5 and 6, respectively, \( P < 0.001 \)). Rats with RIPerc showed a preserved LVEF (72 ± 2% vs 66 ± 4%; n = 5 and n = 6 respectively, \( P < 0.05 \) vs MIR), suggesting the benefit of RIPerc on adverse cardiac dysfunction.

**Immunohematochemistry**

There is a more prominent reduction in TH-positive neurons in MIR rats in comparison to MIR + RIPerc rats (Fig. 4). In comparison to Sham rats, the expression of CSPG was markedly increased in MIR rats (Fig. 5), particularly in the infarcted area and border zone. In contrast, in MIR + RIPerc rats, the CSPG expression was similar to the Sham group (Fig. 5). No CD68 + cells were detected in the Sham group (Fig. 5). In contrast, high numbers of CD68 + macrophages were present in the infarcted myocardial tissue of the MIR group, whereas MIR + RIPerc was associated with a reduced influx of CD68 + macrophages (Fig. 5).

**Discussion**

Alterations of cardiac sympathetic-nerve innervation in cardiac diseases have been increasingly noticed. Nevertheless, a therapeutic approach to alleviate cardiac sympathetic dysfunction is limitedly available.

Cardiac sympathetic and parasympathetic innervation plays multiple roles in cardiac physiology and pathophysiology. There is large body of evidence that selective parasympathetic, e.g., vagus nerve stimulation during acute myocardial infarction protects the heart against myocardial IR injury and chronic stimulation of vagus nerve resulted in an improvement on post-MI remodeling and chronic heart failure, respectively [43, 51]. However, large clinical trials failed to show similar benefits in patients with congestive HF [3].

---

**Table 1 Left-ventricular hemodynamic parameters**

| Parameter/group | Sham-OP | MIR | MIR + RIPerc |
|-----------------|---------|-----|--------------|
| n               | 4       | 5   | 6            |
| LVSP (mm Hg)    | 117 ± 5 | 83 ± 5*** | 95 ± 8§      |
| LVEDP (mm Hg)   | 2.46 ± 0.50 | 5.70 ± 1.49*** | 4.18 ± 0.63  |
| + dP/dt (mm Hg/s) | 7074 ± 564 | 4255 ± 380*** | 5139 ± 588§  |
| − dP/dt (mm Hg/s) | − 5879 ± 478 | − 3125 ± 873** | − 3827 ± 669 |
| HR (bpm)        | 258 ± 28 | 257 ± 40 | 244 ± 28     |

LVSP left-ventricular systolic pressure, LVEDP left-ventricular end-diastolic pressure, \( +dP/dt \) peak velocities of pressure change, HR heart rate

Values are mean ± SD; **\( P < 0.01 \) and ***\( P < 0.001 \) Sham vs MIR, and § \( P < 0.05 \) MIR vs MIR + RIPerc

---

**Fig. 4 Immunohematochemistry of tyrosine hydroxylase (TH) positive neurons in the myocardium.** Representative images show TH staining in the anterolateral area of the defect area (at scar region) in the left-ventricular wall in MIR and RIPerc rats. TH-positive signal is extensively reduced in MIR rats after myocardial infarction compared to control area, and less reduction in RIPerc rats.
On the other hand, sympathetic hyperinnervation or denervation in the myocardium is connected to the progression of cardiac dysfunction [40, 42]. Sympathetic denervation typically occurs in the infarcted myocardium and is associated with sudden cardiac death [14, 17]. Impaired innervation was also demonstrated in non-infarcted myocardium in patients with ischemic and dilated cardiomyopathy [42]. Factors affecting SN integrity in infarcted and remote myocardium are largely unknown. Nevertheless, a recent pioneering study by Siebert et al. [44] demonstrated that CSPG expression within the infarcted myocardium delays the sympathetic innervation following MI. Therefore, novel non-invasive methods are urgently needed to visualize cardiac sympathetic (re)innervation in cardiovascular disease and find therapeutic approach to alleviate cardiac sympathetic dysfunction.

Multiple shreds of evidence demonstrated that a portion of dysinnervated but viable myocardium is essential to attenuate cardiac remodeling, improves cardiovascular function [16, 45]. In contrast, denervated but viable myocardium adjacent to infarcted myocardium may be particularly arrhythmogenic and prone to induce ventricular fibrillation and substantial risk for sudden cardiac death [49]. Thus, the non-invasive approach to identify nerve denervation in viable myocardium and scare area is crucial in patients with ischemic heart disease due to MI and may provide surrogate markers for the risk for sudden cardiac death. Recent advantages in cardiac molecular imaging allow for the specific identification of synaptic biomarkers in the cardiac autonomic nervous system.

In the present study, we hypothesized that RIPerc alleviates cardiac sympathetic denervation following myocardial infarction. This was quantified using the state-of-the-art PET imaging in a rat model of myocardial ischemia and chronic reperfusion. There are numbers of study demonstrated the cardioprotective effects of RIC, e.g., preventing cell death of cardiomyocytes in acute MI. Moreover, Gho et al. demonstrated for the first time that the ganglion blocker hexamethonium abolishes cardioprotection established by RIC, suggesting the functional importance of neural (autonomic) pathways mediating this phenomenon [20]. Beside the infarct size limiting effect of RIC, there are only few studies investigated the impact of RIC on post-MI remodeling [41, 50] and no evidence whether RIC acts on SN activity and denervation in the subacute or chronic phase of MI. Therefore, we first assessed IR injury-mediated SN degradation and myocardial viability depletion in a rat model of MIR. Interestingly, RIC presented cardiac protection against sympathetic denervation but has no protecting effect on viable myocardial stunning. These findings demonstrate that the SN might be more susceptible to ischemia injury than the cardiomyocytes. The remaining viable myocardium may preserve elevated SN fibers in RIPerc rats and substantially may preserve cardiac contractile function. In line with that, RIPerc group showed significantly higher LVSP and a tendency to improve diastolic dysfunction (LVEDP) compared to the MIR group as well as showing preserved LVEF, suggesting its benefit on cardiac pump function and adverse post-MI remodeling.

During acute myocardial ischemia, damage to cardiac sympathetic neurons results in the release of norepinephrine into the myocardial interstitial space [2]. In addition, other study demonstrated that after acute dissection of LAD the left ventrolateral cervical cardiac nerve stimulation resulted in increased shortening velocity of the posterial wall in dogs [29]. In the current study, we have not investigated whether cardiac SN reinnervation following myocardial IR injury is associated with the changes of regional contractile (dys)
function. However, further studies are needed to clarify this important issue.

In general, the neuronal damage could be transient or irreversible, depending on the severity and duration of ischemia, and reversible SN dysfunction has been reported, but is slow in patients after MI [17, 33, 42].

Sympathovagal (im)balance is a critical component in the extent of myocardial damage and infarct size in acute MI. Indeed, previous studies demonstrated the critical importance of brain–heart and vago-splenic axis in acute cardio-protection by RIC [6, 35].

However, there is no evidence whether RIC affects myocardial denervation following MI. Chronic elevation of SN activity in the myocardium is a key component of the altered signaling pathways that accompany cardiac remodeling, increasing the risk for sudden cardiac death resulting from hypertension and acute MI [17, 40]. However, denervated myocardium and decrease in SN activity may play a pivotal role in impaired repair and regeneration following cardiac injury due to MI. In addition, recent studies [7, 18] suggest that early sympathetic-nerve denervation increases the risks for sudden cardiac death after MI. Thereby therapeutic manipulation which alleviate cardiac denervation or boost earlier SN reinnervation after MI may result in clinical benefit.

Furthermore, next to the myocardium, there is growing evidence that coronary circulation may undergo denervation after myocardial IR injury; hence, the coronary circulation is substantially affected by sympathetic-nerve activation. Accordingly, Heusch et al. [28] demonstrated that severe coronary artery stenosis significantly stimulates the sympathetic activation and subsequently aggravates myocardial ischemia in dogs. The underlying signaling mechanisms are mediated via alpha-adrenoceptor-mediated effects of sympathetic activation [27, 30]. In addition, Di Carli et al. [13] demonstrated that increases in coronary blood flow in response to sympathetic stimulation correlated with the regional norepinephrine content in the cardiac sympathetic-nerve terminals in transplanted human hearts. This provides a unique platform for studying the vasomotor responses to sympathetic-nerve stimulation in reinnervated heart. In our study, we have not assessed coronary/myocardial blood flow change in correlation to sympathetic-nerve reinnervation post-myocardial infarction with/without RIPerc. Therefore, further studies are warranted to clarify whether the sympathetic reinnervation and activation is associated with a subsequent changes of myocardial blood flow.

With injury or disease, an increase in extracellular CSPG expression is commonly observed close to lesion areas in the brain and spinal cord [44]. A more recent study showed that CSPG present in the cardiac scar after MI prevents sympathetic innervation by binding the neuronal protein tyrosine phosphatase receptor σ (PTPσ) and downstream signaling pathway activation increases the risk for sudden cardiac death [18]. Notably, we found that CSPG expression within the infarction area was markedly increased in rats with MIR, but it expression was substantially decreased in RIPerc animals. Since CSPG overexpression is linked to the increase risk of sudden cardiac death after MI [7], we hypothesize that the reduction of CSPG by RIPerc provides a beneficial effect of long-term survival in patients with MI. However, to translate this, important novel findings as well as benefit of RIPerc to clinic further rigorous and systematic preclinical studies are warranted [34].

Sympathetic denervation in patients with ischemia and reperfusion has been extensively recognized, but the potential effect of reversible SN dysfunction is less widely appreciated. We demonstrated for the first time that RIPerc markedly improved cardiac sympathetic-nerve denervation after MIR, and this was associated with a marked reduction of CSPG expression and inflammation.

Limitations

Certain limitations of our study need to be acknowledged. Gated cardiac perfusion, scans were not performed to determine the cardiac contraction due to high kinetic positron energy and consequently extensive positron range for small animal images. Myocardial infarct size assessment by histology/immunohistochemistry and integrated FDG PET/MR imaging for the assessment of myocardial salvage are widely used in preclinical and clinical studies, respectively [8, 39]. However, our study was not aimed to assess cardiac scar formation/myocardial infarct size due to limited cardiac tissue samples which is a serious limitation. However, we have shown that RIPerc reduces cardiac scar formation in comparison with rats with MIR [41]. In addition, we have not investigated the signaling mechanism is causative linked to decrease in CSPG expression by RIPerc; our study is descriptive in this context. Furthermore, we can only speculate that RIPerc substantially reduces the risk of sudden cardiac death in our experimental model. Therefore, further study is warranted to clarify this issue, e.g., comparing the effect of RIPerc vs MIR on the vulnerability of isoproterenol induced arrhythmias. Of course, we cannot exclude that other factors next to CSPG play a pivotal role in RIPerc-induced early SN reinnervation following MI. Therefore, further studies are warranted to explore these potential factors and signaling mechanism.

Conclusion

In this study, we found that remote ischemic perconditioning treatment boosted early innervation of cardiac SN following myocardial IR injury in association with the reduction in
CSPG expression, whereas no net effects on the myocardial metabolism were observed.

Acknowledgements The authors thank Milat Inci (Ludwig Boltzmann Institute for Cardiovascular Research, Vienna, Austria), Sandra Trojanek and Petra Fichtinger (Center for Anatomy and Cell Biology, Medical University Vienna, Austria), Anna Zacher, and Stefanie Ponti (Preliminary Clinical Laboratory, Medical University of Vienna) for technical assistance in laboratory works.

Funding Open access funding provided by Medical University of Vienna. This work was supported by project No. 92iu8 from Austria-Hungary Action Foundation (A.K.) and by an unrestricted research support from Medical University Vienna, Austria). This work was supported by project No. 92öu8 from Austria-Hungary Action Foundation (A.K.) and by an unrestricted research support from Vienna. This work was supported by project No. 92öu8 from Austria-Hungary Action Foundation (A.K.) and by an unrestricted research support from Vienna.

Declarations

Conflicts of interest The authors declare no conflict of interest.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Aikawa T, Naya M, Obara M, Oyama-Manabe N, Manabe O, Magota K, Ito YM, Katoch C, Tamaki N (2017) Regional interaction between myocardial sympathetic denervation, contractile dysfunction, and fibrosis in heart failure with preserved ejection fraction: (11)C-hydroxyephedrine PET study. Eur J Nucl Med Mol Imaging 44(11):1897–1905. https://doi.org/10.1007/s00259-017-3760-y
2. Akiyama T, Yamazaki T (2001) Myocardial interstitial norepinephrine and dihydroxyphenylglycol levels during ischemia and reperfusion. Cardiovasc Res 49(1):78–85. https://doi.org/10.1016/s0008-6363(00)00219-4
3. Anand IS, Konstant MA, Klein HU, Mann DL, Ardell JL, Gregory DD, Massaro JM, Libbuz I, DiCarlo LA, Udelson JIE, Butler J, Parker JD, Teerlink JR (2020) Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. ESC Heart Fail 7(1):75–83. https://doi.org/10.1002/ehf2.12592
4. Barber MJ, Mueller TM, Henry DP, Felten SY, Zipes DP (1983) Transmural myocardial infarction in the dog produces sympathetocmy in noninfarcted myocardium. Circulation 67(4):787–796. https://doi.org/10.1161/01.cir.67.4.787
5. Barton MJ, John JS, Clarke M, Wright A, Ekberg J (2017) The glia response after peripheral nerve injury: a comparison between schwann cells and olfactory ensheathing cells and their uses for neural regenerative therapies. Int J Mol Sci 18(2):287. https://doi.org/10.3390/ijms18020287
6. Basalay MV, Davidson SM, Gourine AV, Yellon DM (2018) Neural mechanisms in remote ischaemic conditioning in the heart and brain: mechanistic and translational aspects. Basic Res Cardiol 113(4):25. https://doi.org/10.1007/s10095-018-0684-z
7. Blake MR, Parrish DC, Stassenka MA, Sueda S, Woodward WR, Habecker BA (2022) Chondroitin sulfate proteoglycan 4,6 sulfation regulates sympathetic nerve regeneration after myocardial infarction. Elife 11:e78387. https://doi.org/10.7554/eLife.78387
8. Botker HE, Hausenloy D, Andreadou I, Antonucci S, Boengler K, Davidson SM, Deswal S, Devala Y, Di Lisa F, Di Sante M, Elfentak P, Femminìò S, García-Dorado D, Giercz Z, Ibanez B, Ilidiromitse K, Kluderci C, Kleinbongard P, Neuhausser M, Ovize M, Pagliaro P, Rabheb-Schmidt M, Ruiz-Meana M, Schlüter KD, Schulz R, Skyschally A, Wilder C, Yellon DM, Ferdinand P, Heusch G (2018) Practical guidelines for rigor and reproducibility in preclinical and clinical studies on cardioprotection. Basic Res Cardiol 113(5):39. https://doi.org/10.1007/s00093-018-0696-8
9. Britsch S (2007) The neuregulin-1/ErbB signaling system in development and disease. Adv Anat Embryol Cell Biol 190:1–65. https://doi.org/10.1007/978-3-540-37107-6
10. Clements MP, Byrne E, Camarillo Guerrero LF, Cattin AL, Zakka L, Ashraf A, Burden JJ, Khadayate S, Lloyd AC, Margerat S, Panninello S (2017) The wound microenvironment reprograms schwann cells to invasive mesenchymal-like cells to drive peripheral nerve regeneration. Neuron 96(1):98–114.e7. https://doi.org/10.1016/j.neuron.2017.09.008
11. Crimi G, Pica S, Raineri C, Bramucci E, De Ferrari GM, Klersy C, Ferlini M, Marinoni B, Repetto A, Romeo M, Rosti V, Massa M, Raisaro A, Leonardo S, Rubartelli P, Oltrona Visconti L, Ferrario M (2013) Remote ischemic preconditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial. JACC Cardiovasc Interv 6(10):1055–1063. https://doi.org/10.1016/j.jcin.2013.05.011
12. Dae MW, Herre JM, O’Connell JW, Botvinick EH, Newman D, Munoz L (1991) Scintigraphic assessment of sympathetic innervation after transmural versus nontransmural myocardial infarction. J Am Coll Cardiol 16(6):1416–1423. https://doi.org/10.1016/s0735-1077(10)00156-4
13. Di Carli MF, Tobes MC, Magner T, Levine AB, Muzik O, Chakraborty P, Levine TB (1997) Effects of cardiac sympathetic innervation on coronary blood flow. N Engl J Med 336(17):1208–1215. https://doi.org/10.1056/NEJM1997042434361703
14. Eskander MA, Adler E, Hoffmayer KS (2020) Arrhythmias and sudden cardiac death in post-cardiac transplant patients. Curr Opin Cardiol 35(3):308–311. https://doi.org/10.1097/hco.0000000000000731
15. Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldua S, Mashate TL Jr, Hutson AD, Dekemp RA, Haka MS, Sajjad M, Cimato TR, Curtis AB, Cain ME, Canty JM Jr (2014) Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 63(2):141–149. https://doi.org/10.1016/j.jacc.2013.07.096
16. Fernandez SF, Ovchinnikov V, Canty JM Jr, Fallavollita JA (2013) Hibernating myocardium results in partial sympathetic denervation and nerve sprouting. Am J Physiol Heart Circ Physiol 304(2):H318-327. https://doi.org/10.1152/ajpheart.00810.2011
17. Fukuda K, Kanazawa H, Aizawa Y, Ardell JL, Shivkumar K (2016) Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial. JACC Cardiovasc Interv 6(10):1055–1063. https://doi.org/10.1016/j.jcin.2013.05.011
18. Gardner RT, Wang L, Lang BT, Cregg JM, Dunbar CL, Woodward WR, Silver J, Ripplinger CM, Habecker BA (2015) Targeting...
protein tyrosine phosphatase σ after myocardial infarction restores cardiac sympathetic innervation and prevents arrhythmias. Nat Commun 6:6235. https://doi.org/10.1038/ncomms7235

19. Gaspar A, Lourenço AP, Pereira M, Azevedo P, Roncon-Albuquerque R Jr, Marques J, Leite-Moreira AF (2018) Randomized controlled trial of remote ischaemic conditioning in ST-elevation myocardial infarction as adjunct to primary angioplasty (RICSTEMI). Basic Res Cardiol 113(3):14. https://doi.org/10.1007/s00395-018-0672-3

20. Gho BC, Schoemaker RG, van den Doel MA, Duncker DJ, Verdouw PD (1996) Myocardial protection by brief ischemia in non-cardiac tissue. Circulation 94(9):2193–2200. https://doi.org/10.1161/01.cir.94.9.2193

21. Hartikainen J, Kuikka J, Mäntysaari A, Länsimies E, Pyörälä K (1996) Sympathetic reinnervation after acute myocardial infarction. Am J Cardiol 77(1):5–9. https://doi.org/10.1016/s0002-9149(97)89125-4

22. Hausenloy DJ, Botker HE, Ferdinandy P, Heusch G, Ng GA, Redington A, Garcia-Dorado D (2019) Cardiac innervation in acute myocardial ischaemia/reperfusion injury and cardioprotection. Cardiovasc Res 115(7):1167–1177. https://doi.org/10.1093/cvr/cvz053

23. Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar DIOPROTECTION COST Action. Basic Res Cardiol 116(1):52. https://doi.org/10.1007/118.313859

24. Hausenloy DJ, Candilio L, Evans R, Ariti C, Jenkins DP, Kolvekar DIOPROTECTION COST Action. Basic Res Cardiol 116(1):52. https://doi.org/10.1007/118.313859

25. Herring N, Kalla M, Paterson DJ (2019) The autonomic nervous system and cardiac arrhythmias: current concepts and emerging therapies. Nat Rev Cardiol 16(12):707–726. https://doi.org/10.1038/s41569-019-0221-2

26. Heusch G (2020) Myocardial ischaemia-reperfusion injury and cardioprotection in perspective. Nat Rev Cardiol 17(12):773–789. https://doi.org/10.1038/s41569-020-0403-y

27. Heusch G, Baumgart D, Camici P, Chilian W, Gregorini L, Hess M, Podesser BK, Kiss A (2019) Integrated FDG PET/MR Imaging for the assessment of myocardial salvage in reperfused acute myocardial infarction. Eur J Nucl Med 373(15):1408–1417. https://doi.org/10.1056/NEJMoa1413534

28. Heusch G, Baumgart D, Camici P, Yellon DM, Bøtker HE, Menasché P, Schlosser C, Ruž-Menua M, Schulz R, Zuerbier CJ, Ferdinandy P, Hausenloy DJ (2021) IMProvining Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic Res Cardiol 116(1):52. https://doi.org/10.1007/s00395-021-00893-5

29. Heusch G, Baumgart D, Camici P, Menasché P, Schlosser C, Ruž-Menua M, Schulz R, Zuerbier CJ, Ferdinandy P, Hausenloy DJ (2021) IMProvining Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic Res Cardiol 116(1):52. https://doi.org/10.1007/s00395-021-00893-5

30. Heusch G, Baumgart D, Camici P, Menasché P, Schlosser C, Ruž-Menua M, Schulz R, Zuerbier CJ, Ferdinandy P, Hausenloy DJ (2021) IMProvining Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic Res Cardiol 116(1):52. https://doi.org/10.1007/s00395-021-00893-5

31. Jensen EC (2013) Quantitative analysis of histological staining and fluorescence using ImageJ. Anat rec (Hoboken, NJ: 2007) 296(3):378–381. https://doi.org/10.1002/ar.22641

32. Kleinbongard P, Amanakis G, Skyschally A, Heusch G (2018) Reflection of cardioprotection by remote ischemic preconditioning in attenuated ST-segment elevation during ongoing coronary occlusion in pigs: evidence for cardioprotection from ischemic injury. Circ Res 122(8):1102–1108. https://doi.org/10.1161/circresaha.118.312784

33. Kleinbongard P, Skyschally A, Heusch G (2017) Cardioprotection by remote ischemic conditioning and its signal transduction. Pflugers Arch 469(2):159–181. https://doi.org/10.1007/s00424-016-1922-6

34. LeCour S, Andreaoudi I, Botker HE, Davidson SM, Heusch G, Ruiz-Meana M, Schulz R, Zuerbier CJ, Ferdinandy P, Hausenloy DJ (2021) IMProvining Preclinical Assessment of Cardioprotective Therapies (IMPACT) criteria: guidelines of the EU-CARDIOPROTECTION COST Action. Basic Res Cardiol 116(1):52. https://doi.org/10.1007/s00395-021-00893-5

35. Lieder HR, Kleinbongard P, Skyschally A, Hagedschuer H, Chilian WM, Heusch G (2018) Vago-splenic axis in signal transduction of remote ischemic preconditioning in pigs and rats. Circ Res 123(10):1152–1163. https://doi.org/10.1161/circresaha.118.313859

36. Mélon P, Schaewiger M (1992) Imaging of metabolism and autonomic innervation of the heart by positron emission tomography. Eur J Nucl Med 19(6):453–464. https://doi.org/10.1007/bf00177375

37. Meybohm P, Bein B, Brosteauo O, Cremer J, Gruenewald M, Stoppe C, Coburn M, Schaelte G, Böning A, Niemann B, Roessner J, Kletzin F, Strouhal U, Reyher C, Laufenberg-Feldmann R, Ferno M, Brandes IF, Bauer M, Stehr SN, Kortgen A, Wittmann M, Baumgarten G, Meyer-Treschan T, Kienbaum P, Heringlake M, Schön J, Sander M, Treskatsch S, Smul T, Wolvender E, Schilling T, Fuernau G, Hasenclever D, Zacharowski K (2015) A multicenter trial of remote ischemic preconditioning for heart surgery. N Engl J Med 373(15):1397–1407. https://doi.org/10.1056/NEJMoa1413579

38. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M,Das SR, de Ferranti S, Despres JP, Fullerton HJ, Howard VJ, Huffman MD, Isasi CR, Jiménez MC, Judd SE, Kissela BM, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Magid DJ, McGuire DK, Mohler ER 3rd, Moy CS, Munter P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Rosamond W, Sorlie PD, Steen J, Towfighi A, Turan TN, Virani SS, Woo D, Yeh RW, Turner MB (2016) Heart disease and stroke statistics-2016 update: a report from the American Heart Association. Circulation 133(4):e38-360. https://doi.org/10.1161/cir.0000000000000350

39. Neness F, Poeppele T, Tegzah E, Heusch P, Nassenstein K, Mahabadi AA, Forsting M, Bockisch A, Erbel R, Heusch G, Schlosser T (2015) Integrated FDG PET/MRI Imaging for the assessment of myocardial salvage in reperfused acute myocardial infarction. Radiology 276(2):400–407. https://doi.org/10.1148/radiol.2015140564

40. Parati G, Esler M (2012) The human sympathetic nervous system: its relevance in hypertension and heart failure. Eur Heart J 33(9):1058–1066. https://doi.org/10.1093/eurheartj/ehs041

41. Pilz PM, Hamza O, Gidlöf O, Gonçalves IF, Tretter EV, Trojanek S, Abraham D, Heber S, Haller PM, Podesser BK, Kiss A (2019) Remote ischemic preconditioning attenuates adverse cardiac remodeling and preserves left ventricular function in a rat model of reperfused myocardial infarction. Int J Cardiol 285:72–79. https://doi.org/10.1016/j.ijcard.2019.03.003
42. Rijnierse MT, Allaart CP, de Haan S, Harms HJ, Huisman MC, Wu L, Beek AM, Lammertsma AA, van Rossum AC, Knaapen P (2015) Sympathetic denervation is associated with microvascular dysfunction in non-infarcted myocardium in patients with cardiomyopathy. Eur Heart J Cardiovasc Imaging 16(7):788–798. https://doi.org/10.1093/ehjci/jev013

43. Sabbah HN (2011) Electrical vagus nerve stimulation for the treatment of chronic heart failure. Cleve Clin J Med 78 Suppl 1(01):S24-29. https://doi.org/10.3949/ccjm.78.s1.04

44. Siebert JR, Conta Steencken A, Osterhout DJ (2014) Chondroitin sulfate proteoglycans in the nervous system: inhibitors to repair. Biomed Res Int. https://doi.org/10.1155/2014/845323

45. Simões MV, Barthel P, Matsumari I, Nekolla SG, Schömig A, Schwaiger M, Schmidt G, Bengel FM (2004) Presence of sympathetically denervated but viable myocardium and its electrophysiologic correlates after early revascularised, acute myocardial infarction. Eur Heart J 25(7):551–557. https://doi.org/10.1016/j.ehj.2004.02.016

46. Stiermaier T, Jensen JO, Rommel KP, de Waha-Thiele S, Fuerneau G, Desch S, Thiele H, Eitel I (2019) Combined intrahospital remote ischemic perconditioning and postconditioning improves clinical outcome in ST-elevation myocardial infarction. Circ Res 124(10):1482–1491. https://doi.org/10.1161/circresaha.118.314500

47. Szabó PL, Dostal C, Pilz PM, Hamza O, Acar E, Watzinger S, Mathew S, Kager G, Hallström S, Podesser BKAK (2021) Remote ischemic perconditioning ameliorates myocardial ischemia and reperfusion-induced coronary endothelial dysfunction and aortic stiffness in rats. J Cardiovasc Pharmacol Ther 26(6):702–713. https://doi.org/10.1177/10742484211031327

48. Szabó PL, Ebner J, Koenig X, Hamza O, Watzinger S, Trojanek S, Abraham D, Todt H, Kubista H, Schicker K, Remy S, Anegon I, Kiss A, Podesser BK, Hilber K (2021) Cardiovascular phenotype of the Dmd(mdx) rat—a suitable animal model for Duchenne muscular dystrophy. Dis Model Mech 14(2):dmm047704. https://doi.org/10.1242/dmm.047704

49. van Weperen VYH, Vos MA, Ajijola OA (2021) Autonomic modulation of ventricular electrical activity: recent developments and clinical implications. Clin Auton Res 31(6):659–676. https://doi.org/10.1007/s10286-021-00823-4

50. Wei M, Xin P, Li S, Tao J, Li Y, Li J, Liu M, Li J, Zhu W, Redington AN (2011) Repeated remote ischemic postconditioning protects against adverse left ventricular remodeling and improves survival in a rat model of myocardial infarction. Circ Res 108(10):1220–1225. https://doi.org/10.1161/circresaha.110.236190

51. Zhou L, Filiberti A, Humphrey MB, Fleming CD, Scherlag BJ, Po SS, Stavrakis S (2019) Low-level transcutaneous vagus nerve stimulation attenuates cardiac remodelling in a rat model of heart failure with preserved ejection fraction. Exp Physiol 104(1):28–38. https://doi.org/10.1113/ep087351